Phuturdex › Diseases › Skin Diseases, Genetic
Drugs in development · updated 30 October 2026
Skin Diseases, Genetic: drugs in development
As of 30 October 2026 there are 4 active clinical trials (recruiting or ongoing, phases I–III) on 7 drugs for skin Diseases, Genetic. One is experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| TilrekimigPF-07275315 | III | 2 | NCT07783425 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DupilumabDUPIXENT | III | 1 | NCT07783425 |
| ApremilastOtezla, Apremilast Accord® | II | 1 | NCT06509984 |
| CephalexinKeftab®, Keflet® | II | 1 | NCT01631617 |
| DoxycyclineDoxycyclin, Lymepak® | II | 1 | NCT01631617 |
| SulfamethoxazoleGantanol®, Gantanol-Ds® | II | 1 | NCT01631617 |
| TrimethoprimPrimsol®, Trimpex 200® | II | 1 | NCT01631617 |
Sorted by most advanced phase and number of active trials.
All 7 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Atopic dermatitis 91 drugs
- Eczema 27 drugs
- Behcet Syndrome 11 drugs
- Dermatitis 29 drugs
- Epidermolysis bullosa dystrophica 8 drugs
- Dyskeratosis congenita 15 drugs
- Skin disease 34 drugs
- Epidermolysis bullosa 6 drugs
- Bone marrow failure 26 drugs
- Hoyeraal-Hreidarsson syndrome 9 drugs
- Pachyonychia congenita 3 drugs
- Junctional epidermolysis bullosa 3 drugs
Broader categories
- Genetic disease 33 drugs
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Skin and connective tissue diseases 3 drugs
- Hypersensitivity 22 drugs
- Skin disease 34 drugs
- Eczematous skin disease 3 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D012873 “Skin Diseases, Genetic”.